AYVAKIT (avapritinib)
TherapyBlueprint Medicines
AYVAKIT (avapritinib) from Blueprint Medicines is a precision therapy used in disorders driven by PDGFRA or KIT alterations.
Approvals
1
Indications
1
Biomarkers
1
Mapped tests
1
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and AYVAKIT. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where AYVAKIT is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Gastrointestinal Stromal Tumors (GIST) Solid Tumor · GIST | PDGFRA
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for AYVAKIT.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering AYVAKIT for eligible patients.
Test
therascreen PDGFRA RGQ PCR Kit
QIAGEN GmbH (Qiagen)
Method
PCR
Specimen
Tissue (FFPE)
1 approvalView test profile →